Ocular Therapeutix annual debt-to-equity ratio
2020
2021
2022
2023
2024
2025
Ocular Therapeutix Debt-to-Equity Ratio Growth & History (OCUL)
Ocular Therapeutix's debt-to-equity ratio was 0.01 for fiscal 2025.
View full Ocular Therapeutix company overviewOcular Therapeutix annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.01 | −0.01 | −62.70% |
| 2024 | 2024-12-31 | 0.02 | −0.17 | −88.05% |
| 2023 | 2023-12-31 | 0.19 | −0.91 | −82.49% |
| 2022 | 2022-12-31 | 1.10 | 0.72 | +185.64% |
| 2021 | 2021-12-31 | 0.39 | −0.05 | −11.52% |
| 2020 | 2020-12-31 | 0.44 | — | — |
Ocular Therapeutix quarterly debt-to-equity ratio
Q3.17
Q1.19
Q2.19
Q3.19
Q2.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.01 | −0.01 | −44.90% |
| Q1 2026 | 2026-03-31 | 0.01 | −0.01 | −51.81% |
| Q4 2025 | 2025-12-31 | 0.01 | −0.01 | −62.70% |
| Q3 2025 | 2025-09-30 | 0.02 | 0.00 | +19.20% |
| Q2 2025 | 2025-06-30 | 0.02 | 0.00 | +11.95% |
| Q1 2025 | 2025-03-31 | 0.03 | 0.01 | +35.53% |
| Q4 2024 | 2024-12-31 | 0.02 | −0.17 | −88.05% |
| Q3 2024 | 2024-09-30 | 0.02 | −2.26 | −99.09% |
| Q2 2024 | 2024-06-30 | 0.02 | −12.74 | −99.84% |
| Q1 2024 | 2024-03-31 | 0.02 | −4.03 | −99.52% |
| Q4 2023 | 2023-12-31 | 0.19 | −0.91 | −82.49% |
| Q3 2023 | 2023-09-30 | 2.28 | 1.53 | +205.28% |
| Q2 2023 | 2023-06-30 | 12.76 | 12.24 | +2344.87% |
| Q1 2023 | 2023-03-31 | 4.05 | 3.62 | +845.01% |
| Q4 2022 | 2022-12-31 | 1.10 | 0.72 | +185.64% |
| Q3 2022 | 2022-09-30 | 0.75 | 0.36 | +92.90% |
| Q2 2022 | 2022-06-30 | 0.52 | 0.10 | +24.61% |
| Q1 2022 | 2022-03-31 | 0.43 | 0.03 | +6.88% |
| Q4 2021 | 2021-12-31 | 0.39 | −0.05 | −11.52% |
| Q3 2021 | 2021-09-30 | 0.39 | — | — |
| Q2 2021 | 2021-06-30 | 0.42 | −6.29 | −93.76% |
| Q1 2021 | 2021-03-31 | 0.40 | — | — |
| Q4 2020 | 2020-12-31 | 0.44 | — | — |
| Q2 2020 | 2020-06-30 | 6.71 | 2.54 | +60.95% |
| Q3 2019 | 2019-09-30 | 2.96 | — | — |
| Q2 2019 | 2019-06-30 | 4.17 | — | — |
| Q1 2019 | 2019-03-31 | 1.23 | — | — |
| Q3 2017 | 2017-09-30 | 0.50 | — | — |
Ocular Therapeutix debt-to-equity ratio trends
Over the last five fiscal years, Ocular Therapeutix's debt-to-equity ratio decreased from 0.44 to 0.01, a change of −0.43. The latest reported quarter, Q2 2026, shows 0.01.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ocular Therapeutix source filings ↗